Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

Journal for ImmunoTherapy of Cancer

John M. Kirkwood¹  Lisa H. Butterfield¹  Cindy Sander¹  Usha Malhotra¹  Yan Lin¹  Haris Zahoor¹  Ahmad A. Tarhini¹ 

[1] University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue (555), Pittsburgh 15232, PA, USA

关键词: Cytokines;    Neoadjuvant;    CTLA4;    Ipilimumab;    Melanoma;   

Others  :  1228265
DOI  :  10.1186/s40425-015-0081-1

 received in 2015-05-19, accepted in 2015-07-10,  发布年份 2015

【 摘 要 】

Background

We evaluated candidate circulating serum cytokines, chemokines and growth factors in patients with locally/regionally advanced melanoma receiving neoadjuvant ipilimumab with toxicity and clinical outcome.

Methods

Patients were treated with ipilimumab (10 mg/kg IV every 3 weeks, 2 doses) before and after surgery. xMAP multiplex serum testing for 36 functionally selected cytokines and chemokines was performed at baseline and at six weeks (following ipilimumab). Based on our prior data, the association of IL-17 and immune related colitis was tested. Serum cytokines were divided into functional groups (Th1, Th2, Regulatory, Proinflammatory) and were assessed at baseline and week 6 using sparse-group Lasso modeling to assess the association of various cytokine groups with progression free survival (PFS). The linear combination of the cytokines/chemokines in this model was then used as a risk score and a Kaplan-Meier curve was generated to examine the association of the dichotomized score and PFS.

Results

Thirty-five patients were enrolled whose staging was: IIIB (3; N2b), IIIC (30; N2c, N3), IV (2). Median follow-up was 18 months. Among 33 evaluable patients, median PFS was 11 months (95 % CI = 6.2–19.2). IL-17 was found to correlate significantly with the incidence of grade 3 diarrhea/colitis when measured at baseline (p = 0.02) with a trend towards significance at 6 weeks (p = 0.06). In the modeling analysis, at baseline, the linear combination of 2 regulatory cytokines [TGF- β1 (ρ = 0.19) and IL-10 (ρ = -0.34)] was significantly associated with PFS (HR 2.66; p = 0.035). No significant correlations with clinical outcomes were found in examining the week 6 cytokines.

Conclusions

Baseline IL-17 level was significantly associated with the later development of severe diarrhea/colitis while the combination of baseline TGF- β1 and IL-10 levels were associated with therapeutic clinical outcome after neoadjuvant ipilimumab. These findings warrant further investigation and validation.

Trial registration

ClinicalTrials.gov Identifier NCT00972933.

【 授权许可】

   
2015 Tarhini et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K et al.. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg. 1993; 218:262-7.
• [2]Balch CM, Soong SJ, Smith T, Ross MI, Urist MM, Karakousis CP et al.. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1–4 mm melanomas. Ann Surg Oncol. 2001; 8:101-8.
• [3]Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol. 1996; 3:446-52.
• [4]Tarhini AA, Butterfield LH, Shuai Y, Gooding WE, Kalinski P, Kirkwood JM. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-alpha or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunother. 2012; 35:702-10.
• [5]Tarhini AA, Lin Y, Yeku O, LaFramboise WA, Ashraf M, Sander C et al.. A four-marker signature of TNF-RII, TGF-alpha, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. J Transl Med. 2014; 12:19. BioMed Central Full Text
• [6]Tarhini AA, Shin D, Lee SJ, Stuckert J, Sander CA, Kirkwood JM. Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. Melanoma Res. 2014; 24:150-7.
• [7]Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al.. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363:711-23.
• [8]Pennock GK, Waterfield W, Wolchok JD. Patient Responses to Ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses? Am J Clin Oncol. 2012; 35:606-11.
• [9]Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H et al.. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014; 9: Article ID e87705
• [10]Abraham C, Cho J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15:1090-100.
• [11]Butterfield LH, Potter DM, Kirkwood JM. Multiplex serum biomarker assessments: technical and biostatistical issues. J Transl Med. 2011; 9:173. BioMed Central Full Text
• [12]Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT et al.. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res. 2007; 13:2422-8.
• [13]Wittke F, Hoffmann R, Buer J, Dallmann I, Oevermann K, Sel S et al.. Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br J Cancer. 1999; 79:1182-4.
• [14]Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H et al.. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer. 1994; 69:911-3.
• [15]Mouawad R, Rixe O, Meric JB, Khayat D, Soubrane C. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study. Cytokines Cellular Mol Ther. 2002; 7:151-6.
• [16]Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res. 1995; 5:67-8.
• [17]Tarhini AA, Lin Y, Lin HM, Sander C, Framboise WA, Kirkwood JM. Immune related melanoma gene expression profile predicts neoadjuvant ipilimumab clinical benefit. AACR Annual Meeting. 2014.
• [18]Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A et al.. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371:2189-99.
• [19]Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L et al.. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515:568-71.
• [20]Callahan MK, Yang A, Tandon S, Xu Y, Wolchok JD. Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis. J Clin Oncol. 2011; 29(suppl; abstr 2505):2011.
• [21]Weber JS, O’Day S, Urba W, Powderly J, Nichol G, Yellin M et al.. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008; 26:5950-6.
• [22]Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC et al.. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005; 23:6043-53.
• [23]Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ et al.. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003; 100:8372-7.
• [24]Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US et al.. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005; 28:593-8.
• [25]Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE et al.. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006; 24:2283-9.
• [26]Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE et al.. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007; 13:6681-8.
• [27]Shetty G, Beasley GM, Sparks S, Barfield M, Masoud M, Mosca PJ et al.. Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion. Ann Surg Oncol. 2013; 20:1128-35.
• [28]Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B et al.. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol. 2009; 27:2645-52.
• [29]Patil AS, Sable RB, Kothari RM. An update on transforming growth factor-beta (TGF-beta): sources, types, functions and clinical applicability for cartilage/bone healing. J Cell Physiol. 2011; 226:3094-103.
• [30]Tas F, Karabulut S, Yasasever CT, Duranyildiz D. Serum transforming growth factor-beta 1 (TGF-beta1) levels have diagnostic, predictive, and possible prognostic roles in patients with melanoma. Tumour Biol. 2014; 35:7233-7.
• [31]Ciftci R, Tas F, Yasasever CT, Aksit E, Karabulut S, Sen F et al.. High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer. Tumour Biol. 2014; 35:6941-8.